TriangleFludarabine (NCT05909059)
Fludarabine trial for Non-hodgkin Lymphoma,B Cell (NCT05909059). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with kidney impairment receiving commercial CAR-T therapy for myeloma, leukemia or lymphoma. Kidney function must be at or below 60 milliliters per minute per 1.73 square meters.
The idea: adjust lymphodepleting chemotherapy before CAR-T infusion. Fludarabine interrupts DNA synthesis; cyclophosphamide damages DNA. Fludarabine doses decrease with renal impairment; dialysis patients also receive less cyclophosphamide. Both are infused on days minus five through minus three. Researchers track cytokine-release syndrome, neurologic toxicity and low blood counts.
This phase 2 study plans 20 patients. Northside Hospital sponsors one recruiting Atlanta site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.